Caladrius Biosciences (NASDAQ:CLBS) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.36) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.20, Fidelity Earnings reports.
Caladrius Biosciences stock traded down $0.68 during midday trading on Friday, reaching $4.53. 21,628 shares of the stock were exchanged, compared to its average volume of 36,147. The firm has a market capitalization of $47.56 million, a PE ratio of -2.54 and a beta of 1.22. Caladrius Biosciences has a 52 week low of $2.91 and a 52 week high of $11.65.
A number of analysts recently commented on the stock. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a research note on Wednesday, September 12th. HC Wainwright upped their price target on shares of Caladrius Biosciences to $15.00 and gave the company a “buy” rating in a research note on Monday, September 10th. Finally, Chardan Capital restated a “buy” rating on shares of Caladrius Biosciences in a research note on Wednesday, August 29th.
About Caladrius Biosciences
Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.
Recommended Story: S&P 500 Index
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.